Blog
RSS FeedPosted by Michael Wonder on 14 Jul 2020
NICE partners with Flatiron Health to develop real world evidence research methodologies
14 July 2020 - Collaboration will help NICE expand use of real world data in service of better outcomes for UK ...
Posted by Michael Wonder on 13 Jul 2020
Are high‐cost drug funding mechanisms fit for purpose? A retrospective study of individual funding requests in an NHS tertiary hospital
13 July 2020 - This paper reports on a retrospective study of individual funding request submissions from a large tertiary hospital ...
Posted by Michael Wonder on 12 Jul 2020
Real world evidence use in assessments of cancer drugs by NICE
10 July 2020 - Single technology assessments published by NICE from April 2011 to October 2018 that evaluated cancer treatments were ...
Posted by Michael Wonder on 12 Jul 2020
Does cost effectiveness analysis really need to abandon the incremental cost effectiveness ratio to embrace net benefit?
10 July 2020 - The central task of cost-effectiveness analysis is to identify strategies that maximise health within finite budgets. ...
Posted by Michael Wonder on 12 Jul 2020
Why it’s time to abandon the ICER
10 July 2020 - The incremental cost-effectiveness ratio (ICER) is the most commonly reported summary measure for economic evaluations of health ...
Posted by Michael Wonder on 11 Jul 2020
NICE backing for Takeda's Adcetris for rare lymphoma
10 July 2020 - Takeda's Adcetris (brentuximab vedotin) has won the backing of the National Institute for Health and Care ...
Posted by Michael Wonder on 09 Jul 2020
NICE signs agreement with Colombia’s Institute of Health Technology Assessment to forge closer working ties
9 July 2020 - Research and knowledge sharing key to collaborative working approach agreed the two agencies. ...
Posted by Michael Wonder on 06 Jul 2020
Innovation through HTA: theme for HTAi 2021 Annual Meeting announced
3 July 2020 - Health Technology Assessment International has announced the theme for the 2021 Annual Meeting which will be held ...
Posted by Michael Wonder on 05 Jul 2020
Britain nears $625 million Sanofi/GSK COVID-19 vaccine deal
5 July 2020 - Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for ...
Posted by Michael Wonder on 05 Jul 2020
Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisals
3 July 2020 - Economic models play a central role in the decision-making process of NICE. ...
Posted by Michael Wonder on 02 Jul 2020
Vertex announces expansion of reimbursement agreement with NHS England to include Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor)
30 June 2020 - Cystic fibrosis patients in England will be among the first in Europe to benefit from access to ...
Posted by Michael Wonder on 01 Jul 2020
NICE publishes final guidance for Tecentriq for 2 indications
1 July 2020 - NICE has released final guidance on the use of atezolizumab by patients with small cell lung ...
Posted by Michael Wonder on 30 Jun 2020
After years of feuds, Vertex and the U.K. government reach a deal over cystic fibrosis medicines
30 June 2020 - U.K. officials and Vertex Pharmaceuticals have finally put to rest a years-long battle over access to ...
Posted by Michael Wonder on 29 Jun 2020
Successful Eloctaq bid should widen access to the drug in the UK
29 June 2020 - The NHS and Sobi UK have come to an agreement that will give people living with ...
Posted by Michael Wonder on 28 Jun 2020
NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances
25 June 2020 - Products which received conditional marketing authorisation or authorisation in exceptional circumstances by European Medicines Agency up to ...